Quince Therapeutics (QNCX) Tax Provisions (2022 - 2026)
Quince Therapeutics (QNCX) posted quarterly Tax Provisions of -$5.3 million for Q1 2026, down 11459.57% year-over-year from N/an in Q1 2025, and up 68.65% quarter-over-quarter from -$17.0 million in Q4 2025.
Quince Therapeutics (QNCX) Tax Provisions (2022 - 2026) Analysis & Trends
Quince Therapeutics' Tax Provisions history runs 5 years deep, the most recent figure standing at -$5.3 million for Q1 2026.
- In Q1 2026, Tax Provisions fell 11459.57% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$22.3 million (down 21796.12% YoY), while the FY2025 annual figure was -$17.0 million, down 19595.4% from the prior year.
- Tax Provisions for Q1 2026 stood at -$5.3 million, up from -$17.0 million in the prior quarter.
- The five-year high for Tax Provisions was $67000.0 in Q2 2025, with the low at -$17.0 million in Q4 2025.
- The 5-year median for Tax Provisions is $10000.0 (2024), against an average of -$1.9 million.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions surged 112.5% in 2024, then tumbled 243371.43% in 2025.
- Quince Therapeutics' Tax Provisions stood at -$284000.0 in 2022, then jumped by 117.96% to $51000.0 in 2023, then plunged by 86.27% to $7000.0 in 2024, then sank by 243371.43% to -$17.0 million in 2025, then surged by 68.65% to -$5.3 million in 2026.
- Business Quant data shows QNCX's Tax Provisions at -$5.3 million in Q1 2026, -$17.0 million in Q4 2025, and -$46000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.34 Mn |
| Dec 31, 2025 | -17.03 Mn |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Mar 31, 2023 | -248,000.00 |
| Jun 30, 2022 | -284,000.00 |